From genomics to multiomics: A broader view of neurological disease
In this paid-for advertorial for the Fall 2026 issue of DDW, Sampled shares insight on neurological disease with a genomics and multiomics lens.
Genomic testing can identify drivers of neurological disease, but many variants remain difficult to interpret. Multiomics helps to close this gap by connecting genetic findings with their functional consequences across molecular layers.
Genomics has driven major advances in neuroscience, enabling the discovery of previously unrecognised disease-associated variants. However, despite these gains, many variants identified through genomic testing remain variants of uncertain significance (VUS), meaning that the available evidence is insufficient to support either a pathogenic or benign classification. The volume of genomic data being generated is currently outpacing our ability to establish clear links between genes, variants, and neurological diseases.
Part of this gap may arise because genomic variants can affect biological function in ways that extend beyond disrupting well-characterised functional protein domains. For example, VUS may alter RNA splicing, transcript abundance, allele-specific expression, protein stability, or gene regulatory activity, making it difficult to determine its functional impact and establish a causal link to disease.
Why neurological disorders are particularly challenging
Neurological disorders are highly heterogeneous and symptoms typically overlap across genetically distinct conditions. At the same time, a single genomic variant can produce different symptoms, ages of onset, and levels of disease severity across individuals. This complexity reflects the interplay of multiple omic layers, cell-cell interactions, and how diseases present across developmental stages, among many other factors. Rare neurological disorders are particularly difficult to diagnose because the available evidence base is often limited. This is particularly true for variants that may be more common in populations that remain underrepresented in reference datasets and clinical variant databases. Differences in gene expression between brain regions and cell types add another layer of complexity, particularly when disease-associated changes are confined to small cellular subpopulations.
The importance of multiomics for bridging the gap
While genomic sequencing has delivered important advances, it is not always sufficient to determine the significance of variants of interest. Resolving VUS requires a broader approach that interrogates additional molecular layers in addition to clinical data such as patient phenotype and family history. Multiomics is the integrated analysis of multiple omic layers, and commonly includes genomics, transcriptomics, and proteomics, as well as epigenomics and, more recently, spatial omics.
RNA: The transcriptome provides more information than simply showing the transcript produced from a genomic variant. Transcriptomic analysis can reveal unusually high or low gene expression relative to controls, and help identify effects such as allelic imbalance. It can also uncover aberrant splicing events such as exon skipping and intron retention, including those caused by cryptic splice sites.
Protein: The proteome is where many of the functional consequences of genomic and transcriptomic changes become apparent. Beyond altering protein function, variants can affect protein stability, promote misfolding, disrupt complex formation, alter cellular trafficking, and cause other downstream effects.
Epigenetics: Non-coding variants can disrupt gene regulation by altering transcription-factor binding, regulatory-element activity, chromatin accessibility, or DNA methylation. Epigenomic profiling can provide evidence linking candidate variants to abnormal RNA or protein expression.
Spatial omics: The effects of genomic and transcriptomic variation often differ between cell types, and neurological phenotypes may arise from changes in small populations of neurons or glial cells. Because bulk omics can mask these signals, single-cell and spatial approaches can help identify the specific cell types and tissue regions where variant-associated effects are present.
While each omic layer provides valuable information independently, integrating them within a single analysis can offer a more comprehensive view of disease mechanisms.
A flexible strategy for unresolved cases
A blanket “all-omics-at-once” strategy is not always the most efficient use of resources. In some cases, genomic testing may identify a well-characterised causal variant, making additional molecular analysis unnecessary. Nonetheless, complementary approaches, including transcriptomics, proteomics, epigenomics, and functional analyses, can provide additional evidence to determine whether a variant has a meaningful biological effect and may uncover changes that genomic analysis alone would miss.
For example, findings at the RNA and protein level may prompt more focused reanalysis of specific DNA regions where an undetected variant may reside. This was demonstrated in a recent study published in NPJ Genomic Medicine, which integrated exome reanalysis with RNA sequencing and quantitative proteomics in 34 individuals with previously unresolved neurodevelopmental disorders. With this approach, RNA or protein outliers helped to guide the identification or reprioritisation of causal variants in five individuals1.
Taken together, multiomics emerges as an important toolkit that works best when implemented strategically to resolve VUS. In some cases, one additional omic layer may provide sufficient evidence, while in others, researchers may need to remain flexible and shift across layers when the current approach reaches a diagnostic dead end.
Simplifying access to multiomics
Implementing this type of flexible multiomics strategy can be challenging when the required expertise, technologies, and sample handling capabilities are distributed across multiple providers. Coordinating workflows across separate vendors can add time and complexity, particularly when researchers need to adapt their work as new findings emerge. As an integrated analytical laboratory and biorepository service provider, Sampled brings cold storage, sample management, and multiomics capabilities together within one organisation and physical location, making it easier for researchers to pursue the approaches most relevant to their study as new data is generated. For unresolved variants, that flexibility can help researchers follow the biology beyond the genome and identify the molecular consequences most informative to their investigation.
References
Chui MMC, Kwong AKY, Leung HYC, et al. An outlier approach: advancing diagnosis of neurological diseases through integrating proteomics into multi-omics guided exome reanalysis. NPJ Genom Med 2025;10(1):36.
From DDW Volume 27 – Issue 4, Fall 2026 – Read the digital issue here
